Yuhan Corporation and AprilBio Jointly Develop New Drug Using SAFA Technology
[Asia Economy Reporter Kim Ji-hee] Yuhan Corporation announced on the 27th that it has signed a joint new drug development memorandum of understanding (MOU) with April Bio, which possesses SAFA technology.
April Bio's SAFA technology is a technique that increases the half-life of recombinant proteins and enables the production of recombinant antibody drugs. Last year, April Bio won the 3rd Biopharmaceutical Award with 'APB-R3,' an anti-inflammatory disease treatment substance developed using this technology.
The two companies plan to conduct joint research for global new drug development utilizing SAFA technology. Yuhan Corporation invested 3 billion KRW as a strategic investor in April Bio last year. April Bio is preparing for a special listing on the KOSDAQ market this year based on technology evaluation.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Lee Jung-hee, CEO of Yuhan Corporation, stated, "We expect to be able to engage in competitive global bio new drug development through this business agreement."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
